{"id": "Consent.html", "displayed_text": "Consent", "label_annotations": {"I have read and understood the instructions.": {"Yes": "I have read and understood the instructions.:::Yes"}, "I have read and understood the content warning.": {"Yes": "I have read and understood the content warning.:::Yes"}, "I want to participate in this research and continue with the study.": {"Yes": "I want to participate in this research and continue with the study.:::Yes"}}, "span_annotations": {}, "behavioral_data": {"time_string": "Time spent: 0d 0h 0m 12s "}}
{"id": "Medicine_tweet_24_p", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Findings In this randomized clinical trial of 512 adults, the proportion achieving ureteral stone expulsion by 28 days was 50% with tamsulosin vs 47% with placebo, a nonsignificant difference. Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage. In the 11 cases for which this algorithm did not yield a clear result, the CT scans were individually reviewed and a consensus was reached.\"><b>Finding:</b></span> Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage.", "label_annotations": {"how-causal-is-the-finding": {"Explicitly states: no relation": "4"}}, "span_annotations": [{"start": 850, "end": 854, "span": "not ", "annotation": "Explicit mentions of no relation"}], "behavioral_data": {"time_string": "Time spent: 0d 0h 0m 44s "}}
{"id": "Medicine_tweet_157_p", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Reduction in pathological consequences following this immunotherapy translated into improved cognitive function using well-established measurements of delay-dependent and spatial learning and memory tests. Therefore, we believe that this report provides compelling evidence that a VLP-based immunotherapy approach can be beneficial in preventing tau pathology and could be applicable to diverse human tauopathies, such as Alzheimer's disease (AD), frontotemporal dementia (FTD), traumatic brain injury (TBI), and chronic traumatic encephalopathy (CTE). In one example, pTau peptide (MAPT 9-8 , pS6/ 4) formulated with an adjuvant (Adju-Phos), induced taureactive antibodies, reduced MC1 and PHF1 positive neurons in the brains of TgP301L mice and rescued cognitive function.\"><b>Finding:</b></span> Therefore, we believe that this report provides compelling evidence that a VLP-based immunotherapy approach can be beneficial in preventing tau pathology and could be applicable to diverse human tauopathies, such as Alzheimer's disease (AD), frontotemporal dementia (FTD), traumatic brain injury (TBI), and chronic traumatic encephalopathy (CTE).", "label_annotations": {"how-causal-is-the-finding": {"No mention of a relation": "1"}}, "span_annotations": {}, "behavioral_data": {"time_string": "Time spent: 0d 0h 1m 29s "}}
{"id": "Causality Examples.html", "displayed_text": "Causality Examples", "label_annotations": {"I carefully went over the examples and the instructions.": {"Yes": "I carefully went over the examples and the instructions.:::Yes"}}, "span_annotations": {}, "behavioral_data": {"time_string": "Time spent: 0d 0h 1m 27s "}}
